Researchers at the Korea Research Institute of Standards and Science (KRISS) have developed a revolutionary catalyst that dramatically boosts the efficiency and affordability of green hydrogen production, paving the way for a sustainable energy future.
Ann Hemingway, Professor of Public Health at Bournemouth University, Dept Medical Science & Public Health, discusses how Equine Assisted Interventions can enhance mental health and wellbeing.
While diabetes has been declared as a signifier for infection complications, researchers now say that data suggests it is three times as likely these individuals have severe COVID or are hospitalised.
In the glacial period, sea ice decreases occurred at a similar time to drastic climate change and created intensive debate among scientists - now, the ICE2ICE project has a conclusive answer for what happened.
In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Dr Sylvie Briand, Director, Global Infectious Hazards Preparedness Department at the World Health Organization, explains how COVID-19 is accompanied by fighting an infodemic.
Rob Solly, Division Head, Defence and Security Analysis, tells us how the Defence Science and Technology Laboratory (Dstl) signals a bright future for SME research in defence and security.
Here, we learn from Crispin Associates Ltd about sustainable IT and its impact on health in the 2020 office through an in-depth look at photocopiers and printers.
Chris Wakefield, Vice President of GOJO Industries-Europe Ltd, explores how businesses can navigate the increase in cleaning products on the market and select products that will best meet their needs.
According to the American Heart Association, women face a stronger heart attack risk than men - they are 20% more likely to develop heart failure, and to die.
Teva and Cephalon faced the €60.5 million antitrust fine, after both companies were found to be actively suppressing the existence of cheaper medicine.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
